|Bid||95.05 x 900|
|Ask||95.27 x 2200|
|Day's range||90.17 - 96.18|
|52-week range||62.48 - 104.81|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||51.10|
|Earnings date||28 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||102.07|
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference (held virtually) on Tuesday, June 9, 2020 at 8:00 a.m. ET.
Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR)Q1 2020 Earnings CallMay 9, 2020, 8:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, welcome to MorphoSys First Quarter 2020 Results Conference Call.
The quarterly results for Incyte Corporation (NASDAQ:INCY) were released last week, making it a good time to revisit...
Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14
Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for 2020 guidance, the commercialization of our products, and our development plans and expectations for the compounds in our pipeline, as well as the development plans of our collaboration partners. With regards to clinical development, as of today, while our late-stage programs remain broadly on track, we anticipate that short-term effects may continue to emerge across different aspects of our global clinical trial programs, including new patient recruitment.
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
Incyte (INCY) delivered earnings and revenue surprises of -3675.00% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
The U.S. services sector data and earnings from media giant Disney and plant-based protein maker Beyond Meat will be in focus on a busy Tuesday.
Incyte (NASDAQ: INCY) has performed well since the beginning of the year. Year to date, the biotech company's shares are up by 19%, while the S&P 500 is down by 11% over the same period. The company is currently trading at 44.2 times future earnings.
Incyte Announces Pivotal REACH2 Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi) versus BAT Patients with Acute GVHD